WEIGHT LOSS SPECIALIST – DHA LAHORE
Advanced triple hormone receptor agonist for weight loss – the next generation of injectable obesity treatment in DHA Lahore.
ریتاٹروٹائیڈ ایک جدید انجیکشن ہے جو تین مختلف ہارمون ریسیپٹرز کو ایک ساتھ فعال کرتا ہے۔ یہ ڈاکٹر رضوان نیازی کی نگرانی میں مکمل طبی معائنے کے بعد تجویز کیا جاتا ہے۔
Retatrutide is a next-generation triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple-action mechanism delivers more powerful metabolic effects than any currently approved weight loss injection.
Phase 2 clinical trials showed 24–29% body weight reduction – results comparable to bariatric surgery. It remains under investigation and is prescribed by Dr. Rizwan Niazi after thorough clinical assessment for suitable patients.
ⓘ Retatrutide is currently in advanced clinical trials. Availability is subject to regulatory status at time of consultation.
By activating three hormone pathways simultaneously, Retatrutide targets appetite, energy use, and fat metabolism at once.
Reduces appetite and slows gastric emptying – the same mechanism as Semaglutide and Liraglutide.
Enhances fat burning and improves insulin sensitivity – the same second receptor targeted by Mounjaro.
Unique to Retatrutide: boosts energy expenditure and directly stimulates fat breakdown – adding a third metabolic advantage.
How Retatrutide compares to currently available weight loss injections.
ⓘ Based on clinical trial data. Results vary by individual. Retatrutide data from Phase 2 trials (Eli Lilly, 2023).
Retatrutide is still in advanced clinical development. It is prescribed only after thorough specialist assessment for appropriately selected patients.
Nausea, vomiting, and decreased appetite are the most commonly reported effects – consistent with other GLP-1 based therapies.
Due to its advanced mechanism, Retatrutide is only prescribed following full metabolic evaluation, including bloodwork and medical history review.
Dr. Rizwan Niazi evaluates each patient individually to determine whether Retatrutide is the appropriate treatment option.
Book a consultation with Dr. Rizwan Niazi to discuss whether Retatrutide is available and appropriate for your case.
Dr. Rizwan also prescribes the following approved injections based on individual patient assessment.
ⓘ All injections are prescribed based on individual assessment under proper medical supervision.
Retatrutide is a powerful triple-receptor agent. A thorough clinical assessment is mandatory before prescribing – including metabolic bloodwork, medical history review, and evaluation of current medications.
Bloodwork including HbA1c, lipids, liver and kidney function are reviewed before Retatrutide is considered.
Regular follow-ups track results and watch for any metabolic changes throughout the treatment period.
Dose is carefully calibrated based on your baseline metabolic profile and response to initial treatment.
Retatrutide, Mounjaro, Wegovy, and Saxenda each target different hormone receptors and suit different patient profiles. A consultation with Dr. Rizwan Niazi determines the safest, most effective option for you.
Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. It is the most advanced weight loss injection currently in clinical development, showing 24–29% body weight reduction in Phase 2 trials.
Retatrutide is currently in advanced Phase 3 clinical trials. Availability for prescription depends on current regulatory status at the time of your consultation. Dr. Rizwan Niazi will advise on what is available and appropriate for your case.
Mounjaro targets two receptors (GLP-1 and GIP). Retatrutide adds a third: glucagon. The glucagon receptor activation directly stimulates fat breakdown and energy expenditure, giving Retatrutide a potential additional metabolic advantage.
Phase 2 trials showed 24–29% body weight reduction over 48–68 weeks – results that are comparable to bariatric surgery outcomes. Phase 3 results are pending full publication.
The most commonly reported side effects in trials are nausea, vomiting, and decreased appetite – consistent with other incretin-based therapies. The full side effect profile will be confirmed through ongoing Phase 3 data.
No. Retatrutide must only be used under direct specialist supervision. A full clinical assessment including bloodwork is required before any prescription is issued.